Shengbai oral liquid has been used in clinical practice for many years as a treatment drug for leukopenia, and in the course of clinical application for many years, it has been found to have good efficacy in the prevention/treatment of leukopenia. In order to better explore the product features and provide more standardized clinical research data for clinicians' reference, Mengyang Pharmaceutical invited the most influential clinical experts, methodological experts and representatives of scientific research institutions from the field of oncology in China and the United States to gather in Beijing on December 15, 2018 to discuss the advantages of Shengbai Oral Liquid in the prevention/treatment of neutropenia after chemotherapy in patients with non-small cell lung cancer, so as to ensure the ongoing "Post-marketing Re-evaluation Multicenter Clinical Study" Scientific evaluation and orderly and standardized implementation of the project.
From more than ten hospitals, including Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Memorial Sloan-Katherine Cancer Center (MSKCC), UT MDAnderson Cancer Center, The First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shanghai Yueyang Hospital, Shanxi Provincial Cancer Hospital, Chinese People's Liberation Army No. 81 Hospital, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Xuzhou Hospital Affiliated to Southeast University School of Medicine, Guangzhou Chest Hospital, etc. More than 20 authoritative oncology experts attended the meeting.
The meeting was presided over by Ms. Zhou Huiying, assistant to the president and deputy general manager of Mengyang Pharmaceutical, and Mr. Zhang Min, chairman of the board, made a warm welcome speech, expressing deep gratitude to the Chinese and foreign experts for their arrival, and hoping to bring Shengbai oral liquid into a new development track through this scientific research project.
At the meeting, Liu Shuo, deputy director of the Department of Oncology of Guang'anmen Hospital, China Academy of Chinese Medical Sciences, introduced in detail to the participating experts the basis, research objectives and clinical protocols of the randomized, controlled and multicenter clinical trial on the effectiveness and safety of Shengbai Oral Liquid in the prevention and treatment of neutropenia during chemotherapy in patients with non-small cell lung cancer, and made a detailed report on the clinical research results of Shengbai Oral Liquid in the prevention and treatment of bone marrow suppression caused by tumor radiotherapy and chemotherapy.
Professor Cen Wenchang from Guangzhou Chest Hospital also shared his experience in the application of Shengbai Oral Liquid in the treatment of leukopenia after chemotherapy in cancer patients. Professor Hua Haiqing from the 81st Hospital of the People's Liberation Army of Chinese China, Professor Xu Yun from Xiyuan Hospital of China Academy of Chinese Medical Sciences, Professor Liu Jie from Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Professor Bao Ting from Memorial Sloan Katherine Cancer Center (MSKCC), Professor Shelley from the Center for Integrative Medicine at UT MDAnderson Cancer Center, Professor Yin Dongfeng from the First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Professor Xu Ling from Shanghai Yueyang Hospital, Professor Xie Ying and other experts from Shanxi Provincial Cancer Hospital also had a heated discussion on program design and clinical research, and put forward valuable suggestions. Experts have said that the development of this project has long-term guiding significance for the prevention and treatment of raw white oral liquid in the prevention and treatment of leukopenia caused by tumor radiotherapy and chemotherapy, and will also provide strong evidence-based medical data support for the application of traditional Chinese medicine in the treatment of tumor radiotherapy and chemotherapy in Western medicine.
Finally, Professor Lin Hongsheng concluded his speech: as a therapeutic drug for the treatment of toxic side effects of anti-tumor drugs, Shengbai oral liquid has a definite effect on the prevention and treatment of leukopenia after bone marrow suppression after tumor chemoradiotherapy, which is worthy of wide clinical application. Therefore, the clinical efficacy of Shengbai Oral Liquid can be verified again by using modern scientific research methods and rigorous scientific research methods to verify the clinical efficacy of traditional Chinese medicine products such as Shengbai Oral Liquid, which can allow more Western medicine doctors or foreign doctors to fully understand the exact efficacy of traditional Chinese medicine, and truly push traditional Chinese medicine to a new height and go to the world. I hope that everyone will seize the great opportunity of the country to vigorously develop traditional Chinese medicine, work hard, study hard, and develop good products like Shengbai oral liquid, so as to better relieve the pain of patients, and I believe that with the joint efforts of everyone, Chinese medicine will shine in the field of tumor treatment in the future!
The participants took a group photo
